Related Experiment Video
Updated: Sep 15, 2025
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.5K
Localized Delivery of the mRNAs Encoding CD47 Inhibitor and Interleukins 12, 15, and 21 Elicits Robust Antitumor
Tao Jiang1,2, Shuaiyang Jing1,2, Haojun Li1,2
1School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|July 13, 2025
Summary
Localized mRNA delivery of CD47 inhibitors, combined with cytokines, enhances cancer immunotherapy. This novel approach overcomes limitations of current therapies, boosting systemic immunity and memory against metastatic tumors.
Area of Science:
- Cancer immunotherapy
- Drug delivery systems
- Molecular and cellular immunology
Background:
- CD47 inhibitors show promise in cancer immunotherapy by blocking the CD47/SIRPα signal, enhancing phagocytosis and antigen presentation.
- Clinical use of CD47 inhibitors is limited by side effects like anemia and hemagglutination, and modest in vivo efficacy.
- Localized delivery strategies are needed to improve therapeutic outcomes and reduce systemic toxicity.
Purpose of the Study:
- To develop a localized delivery strategy for mRNA encoding a CD47 inhibitor using lipid nanoparticles.
- To evaluate the efficacy of combination therapy with CD47 inhibitor mRNA and a cytokine cocktail (IL-12, IL-15, IL-21) for synergistic antitumor effects.
- To investigate the underlying mechanisms of enhanced antitumor immunity and long-lasting memory.
Main Methods:
- Encapsulation of mRNA encoding a secreted CD47 inhibitor into lipid nanoparticles for localized delivery.
- In vitro assessment of macrophage activation against cancer cells.
- In vivo combination therapy using CD47 inhibitor mRNA and a cytokine cocktail, evaluating tumor suppression and systemic immunity.
- Mechanistic studies involving dendritic cell differentiation, T cell cross-priming, and cytotoxic T cell activation.
Main Results:
- mRNA-derived CD47 inhibitor activated macrophages against cancer cells in vitro.
- Combination therapy achieved synergistic antitumor effects, significantly suppressing primary and metastatic tumors.
- The strategy induced robust systemic antitumor immunity and long-lasting immunological memory.
- Mechanisms involved enhanced differentiation of type 1 dendritic cells, improved T cell cross-priming, and augmented cytotoxic T cell activity.
Conclusions:
- Localized mRNA delivery of CD47 inhibitors, especially in combination with cytokines, offers a potent strategy to overcome current therapeutic limitations.
- This approach effectively generates systemic antitumor immunity and immunological memory, crucial for combating metastatic disease.
- The findings present a promising platform for advancing cancer immunotherapy with improved efficacy and potentially reduced side effects.
